Literature DB >> 26190223

Mechanisms of drug resistance: quinolone resistance.

David C Hooper1,2, George A Jacoby3,2.   

Abstract

Quinolone antimicrobials are synthetic and widely used in clinical medicine. Resistance emerged with clinical use and became common in some bacterial pathogens. Mechanisms of resistance include two categories of mutation and acquisition of resistance-conferring genes. Resistance mutations in one or both of the two drug target enzymes, DNA gyrase and DNA topoisomerase IV, are commonly in a localized domain of the GyrA and ParE subunits of the respective enzymes and reduce drug binding to the enzyme-DNA complex. Other resistance mutations occur in regulatory genes that control the expression of native efflux pumps localized in the bacterial membrane(s). These pumps have broad substrate profiles that include quinolones as well as other antimicrobials, disinfectants, and dyes. Mutations of both types can accumulate with selection pressure and produce highly resistant strains. Resistance genes acquired on plasmids can confer low-level resistance that promotes the selection of mutational high-level resistance. Plasmid-encoded resistance is due to Qnr proteins that protect the target enzymes from quinolone action, one mutant aminoglycoside-modifying enzyme that also modifies certain quinolones, and mobile efflux pumps. Plasmids with these mechanisms often encode additional antimicrobial resistances and can transfer multidrug resistance that includes quinolones. Thus, the bacterial quinolone resistance armamentarium is large.
© 2015 New York Academy of Sciences.

Entities:  

Keywords:  DNA gyrase; efflux pumps; plasmids; quinolone; topoisomerase

Mesh:

Substances:

Year:  2015        PMID: 26190223      PMCID: PMC4626314          DOI: 10.1111/nyas.12830

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  239 in total

Review 1.  The mar regulon: multiple resistance to antibiotics and other toxic chemicals.

Authors:  M N Alekshun; S B Levy
Journal:  Trends Microbiol       Date:  1999-10       Impact factor: 17.079

2.  Interplay between the MexA-MexB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa.

Authors:  X Z Li; L Zhang; K Poole
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

3.  The homodimeric ATP-binding cassette transporter LmrA mediates multidrug transport by an alternating two-site (two-cylinder engine) mechanism.

Authors:  H W van Veen; A Margolles; M Müller; C F Higgins; W N Konings
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

4.  Quaternary changes in topoisomerase II may direct orthogonal movement of two DNA strands.

Authors:  D Fass; C E Bogden; J M Berger
Journal:  Nat Struct Biol       Date:  1999-04

5.  Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.

Authors:  X S Pan; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

6.  Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis.

Authors:  B Fournier; X Zhao; T Lu; K Drlica; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

7.  NorM of vibrio parahaemolyticus is an Na(+)-driven multidrug efflux pump.

Authors:  Y Morita; A Kataoka; S Shiota; T Mizushima; T Tsuchiya
Journal:  J Bacteriol       Date:  2000-12       Impact factor: 3.490

8.  Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa.

Authors:  N Masuda; E Sakagawa; S Ohya; N Gotoh; H Tsujimoto; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

9.  A new two-component regulatory system involved in adhesion, autolysis, and extracellular proteolytic activity of Staphylococcus aureus.

Authors:  B Fournier; D C Hooper
Journal:  J Bacteriol       Date:  2000-07       Impact factor: 3.490

10.  Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia.

Authors:  A Alonso; J L Martínez
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

View more
  128 in total

1.  De Novo Characterization of Genes That Contribute to High-Level Ciprofloxacin Resistance in Escherichia coli.

Authors:  Thu Tran; Qinghong Ran; Lev Ostrer; Arkady Khodursky
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

2.  Resistance and Virulence Mechanisms of Escherichia coli Selected by Enrofloxacin in Chicken.

Authors:  Jun Li; Haihong Hao; Menghong Dai; Heying Zhang; Jianan Ning; Guyue Cheng; Muhammad Abu Bakr Shabbir; Abdul Sajid; Zonghui Yuan
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

3.  Circulation of Plasmids Harboring Resistance Genes to Quinolones and/or Extended-Spectrum Cephalosporins in Multiple Salmonella enterica Serotypes from Swine in the United States.

Authors:  Ehud Elnekave; Samuel L Hong; Seunghyun Lim; Shivdeep S Hayer; Dave Boxrud; Angela J Taylor; Victoria Lappi; Noelle Noyes; Timothy J Johnson; Albert Rovira; Peter Davies; Andres Perez; Julio Alvarez
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

4.  Rapid Evolution of Reduced Susceptibility against a Balanced Dual-Targeting Antibiotic through Stepping-Stone Mutations.

Authors:  Petra Szili; Gábor Draskovits; Tamás Révész; Ferenc Bogár; Dávid Balogh; Tamás Martinek; Lejla Daruka; Réka Spohn; Bálint Márk Vásárhelyi; Márton Czikkely; Bálint Kintses; Gábor Grézal; Györgyi Ferenc; Csaba Pál; Ákos Nyerges
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

Review 5.  What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Authors:  Karen Bush; Malcolm G P Page
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-04       Impact factor: 2.745

Review 6.  Topoisomerases as anticancer targets.

Authors:  Justine L Delgado; Chao-Ming Hsieh; Nei-Li Chan; Hiroshi Hiasa
Journal:  Biochem J       Date:  2018-01-23       Impact factor: 3.857

7.  Isolation and molecular characterization of group B Streptococcus from laboratory Long-Evans rats (Rattus norvegicus) with and without invasive group B streptococcal disease.

Authors:  Caroline Bodi Winn; Vasudevan Bakthavatchalu; Michael Y Esmail; Yan Feng; JoAnn Dzink-Fox; Lauren Richey; Scott E Perkins; Eric K Nordberg; James G Fox
Journal:  J Med Microbiol       Date:  2018-01       Impact factor: 2.472

8.  Synergistic Quinolone Sensitization by Targeting the recA SOS Response Gene and Oxidative Stress.

Authors:  S Diaz-Diaz; E Recacha; J Machuca; A García-Duque; F Docobo-Pérez; J Blázquez; A Pascual; J M Rodríguez-Martínez
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

9.  Genomic analysis of the multi-drug-resistant clinical isolate Myroides odoratimimus PR63039.

Authors:  Shaohua Hu; Tao Jiang; Yajun Zhou; Desong Ming; Hongzhi Gao; Mingxi Wang
Journal:  Mol Genet Genomics       Date:  2016-10-28       Impact factor: 3.291

10.  Urinary Tract Physiological Conditions Promote Ciprofloxacin Resistance in Low-Level-Quinolone-Resistant Escherichia coli.

Authors:  Guillermo Martín-Gutiérrez; Jerónimo Rodríguez-Beltrán; José Manuel Rodríguez-Martínez; Coloma Costas; Javier Aznar; Álvaro Pascual; Jesús Blázquez
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.